Ophthalmology

Aerie Pharmaceuticals, a company dedicated to small molecule treatments for glaucoma, named Thomas Mitro president and chief operating officer.

Ksenia Stafeeva, MD, is joining New Eyes, a Las Vegas-based LASIK and ophthalmology practice.

Alpharetta, Ga.-based Clearside Biomedical named Glenn Noronha, PhD, as executive vice president of research and development.

Ophthalmologist John Ervin, MD, has been elected president of the Georgia Society of Ophthalmology, according to a report in The Telegraph.

Kenneth B. Simons, MD, board-certified ophthalmologist, has been elected the State of Wisconsin Medical Examining Board chairman, according to a Wauwatosa Now report.

Omeros, a clinical stage biopharmaceutical company, has announced that has submitted a new drug application to the FDA for its OMS302, a drug for use during intraocular lens replacement surgery.

The global market for surgical ophthalmology devices was valued at $7.4 billion in 2012 and is expected to reach $9 billion in 2017, according to a Research and Markets report.

The United States Preventative Task Force has released a recommendation statement for glaucoma screening in the Annals of Internal Medicine.

Valeant expects to reduce its combined workforce by 10 to 15 percent upon completion of the $8.7 billion Bausch + Lomb buyout, according to a Healio report.

Grand Traverse Ophthalmology Clinic in Traverse City, Mich., added J. Ryan McManus, MD, to its staff.